Federal contract award
75A50120C00198
DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $16.4M |
| Current contract value | $16.4M |
| Potential contract value / ceiling | $16.4M |
| Start date | Sep 30, 2020 |
| Current end date | Jun 30, 2026 |
| Potential end date | Jun 30, 2026 |
| Latest award activity | Mar 11, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 14 of 14 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 11, 2026 | P00013 | $0 | EOI: PRESIDENTIAL COST SAVINGS INITIATIVE (FEBRUARY 26, 2025): EOI NOTICE OF TERMINATION FOR CONVENIENCE |
| Feb 13, 2026 | P00012 | $0 | EOI: PRESIDENTIAL COST SAVINGS INITIATIVE (FEBRUARY 26, 2025): EOI NOTICE OF TERMINATION FOR CONVENIENCE |
| Nov 19, 2024 | P00011 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0001 TO ALIGN WITH IPP. |
| Aug 20, 2024 | P00010 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO UPDATE ARTICLE G.7 INDIRECT COST RATE BASED ON DOCUMENTATION FROM NIH DATED AUGUST 2, 2024. |
| Jun 24, 2024 | P00009 | $109.5K | THE PURPOSE OF THIS IS TO UPDATE ARTICLES B.2, B.3, F.2(A) AND ARTICLE G.1, G.5, EXTEND POP FOR CLIN 0001, CLIN 0004, CLIN 0005, AND PROVIDE SUPPLEMENTAL FUNDING UNDER CLIN0001. |
| Nov 3, 2023 | P00008 | $0 | ADMINISTRATIVE ACTION |
| Jun 29, 2023 | P00007 | $718.2K | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 4/CLIN0005, NO-COST EXTENSION OF CLIN0001 THROUGH 6/30/2024, AND REVISE TRAVEL COSTS |
| May 3, 2023 | P00006 | $1.5M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 3 CLIN0004, UPDATE SOW, PROVIDE ADDITIONAL FUNDING FOR CLIN0001, ESTABLISH OPTION 4 CLIN0005, AND EXTEND THE PERIOD OF PERFORMANCE (POP) FOR CLIN0001 |
| Jan 30, 2023 | P00005 | $0 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE |
| Aug 15, 2022 | P00004 | $4.5M | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE |
| Jun 2, 2022 | P00003 | $4.7M | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE |
| Nov 2, 2021 | P00002 | $0 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE |
| Sep 9, 2021 | P00001 | $444.3K | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE |
| Sep 28, 2020 | 0 | $4.5M | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.